Recently, eBioMedicine, a journal within the The Lancet family, published a study entitled "Modified hTERT treatment ameliorates pressure overload-induced heart failure." The research describes an innovative gene therapy, JV101, which drives the expression of a modified human telomerase reverse transcriptase (modhTERT). Through telomere restoration, the therapy was shown to improve mitochondrial function, reduce chronic inflammation, and ultimately mitigate the progression of heart failure.
As a preclinical non-human primate disease models research partner, Prisys Biotechnologies provided high-quality cynomolgus monkey heart failure tissue samples that supported the validation of key pathological mechanisms in a translationally relevant large-animal model. The study highlights the critical role of NHP models in bridging fundamental discoveries and clinical development.
Validating the Link Between Telomere Dysfunction and Heart Failure in NHPs
Telomere shortening has long been associated with aging and cardiovascular disease. However, direct evidence linking telomere dysfunction to heart failure progression in higher mammals has remained limited.
![Paraffinembedded NHP cardiac samples were used for telomere Q-FISH quantification of CMs. NHP CMs (cardiac Troponin-T [green]) were stained for telomere (red) and for nuclear DAPI (blue) in heart failure and control cardiac tissue sections. Masson's trichrome staining was performed to confirm cardiac fibrosis in failing NHP hearts (healthy NHP, n = 3; HF NHP, n = 3).](/uploads/39406/news/p202606021422106ad66.png?size=691x0 "Paraffinembedded NHP cardiac samples were used for telomere Q-FISH quantification of CMs. NHP CMs (cardiac Troponin-T [green]) were stained for telomere (red) and for nuclear DAPI (blue) in heart failure and control cardiac tissue sections. Masson's trichrome staining was performed to confirm cardiac fibrosis in failing NHP hearts (healthy NHP, n = 3; HF NHP, n = 3).")
stained for telomere (red) and for nuclear DAPI (blue) in heart failure and control cardiac tissue sections. Masson's trichrome staining was
performed to confirm cardiac fibrosis in failing NHP hearts (healthy NHP, n = 3; HF NHP, n = 3).
To strengthen translational relevance, the investigators incorporated non-human primate heart failure models into their research strategy. Using cardiac tissues supplied by Prisys Biotechnologies, the team conducted comprehensive analyses that revealed several hallmark features of heart failure, including:
- Significant reduction in cardiomyocyte telomere signals;
- Increased myocardial fibrosis;
- Elevated expression of B-type natriuretic peptide (BNP);
- A strong correlation between telomere integrity and cardiac function parameters, including left ventricular ejection fraction (LVEF).
These findings demonstrated that telomere attrition is closely associated with heart failure progression in non-human primates, mirroring observations reported in human patients. The results provided important mechanistic support for the therapeutic rationale behind JV101 and reinforced the translational value of NHP cardiovascular models.
Why Non-Human Primate Models Matter in Cardiovascular Translational Research
Rodent models remain indispensable for early-stage mechanistic studies, but their ability to predict clinical outcomes is often limited by substantial differences in cardiovascular anatomy, physiology, and disease progression.
Non-human primates offer several advantages for translational cardiovascular research:
- Cardiac anatomy and coronary circulation patterns closely resemble those of humans;
- Electrophysiological characteristics are more clinically relevant;
- Disease progression better reflects human cardiovascular pathology;
- Immune responses are more predictive for evaluating advanced therapeutics such as gene and cell therapies.
As a result, NHP models have become an important translational bridge for the development of novel gene therapies, RNA-based medicines, and regenerative medicine approaches targeting cardiovascular diseases.
The successful application of NHP tissues in this study further demonstrates the value of high-fidelity disease models in supporting translational decision-making and de-risking clinical development.
Prisys Biotechnologies' NHP Cardiovascular and Disease Model Platform
Prisys Biotechnologies specializes in non-human primate disease models and translational in vivo research. The company has established a portfolio of standardized NHP models spanning cardiovascular, hematological, and central nervous system indications, including:
Supported by advanced interventional capabilities, multimodal clinical imaging platforms, and extensive experience in in vivo pharmacology studies, Prisys provides comprehensive preclinical research support for innovative therapeutics, including biologics, gene therapies, and cell-based therapies.
Services include disease model development, pharmacokinetic/pharmacodynamic (PK/PD) studies, efficacy evaluation, biomarker assessment, and translational research designed to generate clinically relevant data for drug development programs.
Looking Ahead
As cardiovascular therapeutics continue to evolve toward regenerative medicine and gene-based interventions, the demand for translationally relevant preclinical models will continue to grow.
The contribution of NHP heart failure tissues to this telomere restoration gene therapy study underscores the importance of advanced large-animal models in validating disease mechanisms and accelerating therapeutic innovation.
Leveraging its expertise in non-human primate disease models, in vivo pharmacology, and translational research, Prisys Biotechnologies remains committed to supporting the development of next-generation cardiovascular therapies and helping bridge the gap between laboratory discoveries and clinical application.
Zhao Y, Bao X, Xiong W, et al. Modified hTERT treatment ameliorates pressure overload-induced heart failure. EBioMedicine. 2026;126. DOI: 10.1016/j.ebiom.2026.106203.
FAQ
Q: What role did Prisys Biotechnologies play in the eBioMedicine gene therapy study?
A: Prisys Biotechnologies provided high-quality cynomolgus monkey heart failure tissue samples that supported the validation of key pathological mechanisms, demonstrating the link between telomere dysfunction and heart failure progression in a translationally relevant large-animal model.
Q: Why are non-human primate (NHP) models preferred over rodents in cardiovascular research?
A: NHPs possess cardiac anatomy, coronary circulation patterns, electrophysiological characteristics, and immune responses that closely resemble humans, making them highly effective translational bridges for advanced therapeutics like gene and cell therapies.
Q: What types of NHP cardiovascular and hematological disease models does Prisys offer?
A: Prisys offers a comprehensive portfolio of standardized NHP models, including Acute Myocardial Infarction (AMI), Heart Failure (HF), Hemophilia A, Arteriovenous (A-V) Shunt Thrombosis, and Acute Blood Loss/Shock.
